← Vetted

Elliot Marsh

Biohacking & Longevity Research

Health coach and independent researcher in longevity science. Background in biochemistry.

NOVOS Core

Multi-pathway longevity formula

Approved

→

CircO2

Nitric oxide support

Caveat

→

FlexBeam

Targeted red light therapy

Approved

→

ReadyRx NAD+

NAD+ precursor

Caveat

→

NOVOS Core

Approved

Multi-pathway longevity formula targeting twelve hallmarks of aging simultaneously. Seven of its twelve ingredients carry published human trial data at or near the doses included. The synergy across hallmarks is a structural strength that single-ingredient alternatives cannot replicate.

12 ingredients, all doses declared — no proprietary blend
RCT on the complete formula: BP −8.5 mmHg, arterial stiffness improved (preprint, peer review pending)
7 of 12 ingredients carry published human trial data at or near included doses
Advisory board includes researchers from Harvard, Salk Institute, and U. of Washington
Fisetin at 100mg delivers antioxidant benefit, not senolytic clearance

Get the full report

Enter your email — we'll send it directly.

One-time delivery only — not a subscription.

View NOVOS Core

CircO2

Caveat

Nitric oxide support via beetroot and hawthorn with clinical dosing within published ranges. The lozenge delivery format offers measurably higher bioavailability than capsule alternatives for the nitrate pathway. Evidence supports cardiovascular and exercise performance benefits in adults over 40.

Lozenge format delivers nitrate directly to oral bacteria — effects at 20 minutes
Dual-pathway design: addresses both eNOS decline and entero-salivary NO loss
Placebo-controlled crossover study: systolic BP −6 mmHg at 60 min
Hawthorn: highest nitrite reductase activity of 100+ botanicals screened
420mg proprietary blend — individual ingredient doses not verifiable
Study used equivalent formulation, not CircO2 specifically

Get the full report

Enter your email — we'll send it directly.

One-time delivery only — not a subscription.

View CircO2

FlexBeam

Approved

Targeted red light therapy device operating at clinically documented wavelengths. The portable form factor and focused beam design address a practical gap in home-use photobiomodulation that panel-style devices leave open. Published pilot data supports joint and tissue recovery applications.

Wavelengths 610–850nm, irradiance 110 mW/cm² — within clinical study parameters
Contact design eliminates distance losses that undermine panel devices
34-RCT meta-analysis supports PBM for muscle recovery and DOMS reduction
Red light at 610–650nm does not suppress melatonin — safe for evening use
No FlexBeam-specific RCTs — evidence extrapolated from PBM category

Get the full report

Enter your email — we'll send it directly.

One-time delivery only — not a subscription.

View FlexBeam

ReadyRx NAD+

Caveat

NAD+ precursor supplement combining NMN with complementary cofactors for cellular energy metabolism. The formulation addresses the well-documented age-related decline in NAD+ levels with ingredients that have individual clinical support. Dosing aligns with published intervention ranges.

Access to both branded GLP-1 (Wegovy, Zepbound) and compounded options
Every compounded order third-party tested: potency, sterility, pH, endotoxicity
LegitScript certified; zero FDA warning letters despite 80+ sector-wide
Branded GLP-1 evidence: 14.9–22.5% mean weight loss (STEP/SURMOUNT trials)
NAD+ injectable outcome data in healthy adults is early-stage
Metformin TAME trial results pending; may blunt exercise adaptations

Get the full report

Enter your email — we'll send it directly.

One-time delivery only — not a subscription.

View ReadyRx NAD+

Elliot Marsh

NOVOS Core

CircO2

FlexBeam

ReadyRx NAD+

NOVOS Core

Get the full report

CircO2

Get the full report

FlexBeam

Get the full report

ReadyRx NAD+

Get the full report

Report sent